https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2016-01720
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in...
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections...
efficacy and safety
https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2016.01317/full
Frontiers | Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir...
Human cytomegalovirus (HCMV) is a significant pathogen in immunocompromised individuals, with the potential to cause fatal pneumonitis and colitis, as well a...
multi drug resistancelow frequency
https://www.takeda.com/newsroom/shire-news-releases/2016/n95to3/
Results from Shire's Phase 2 Study of Maribavir Showed Activity Against CMV Infection in Patients...
Results from Shire's Phase 2 Study of Maribavir Showed Activity Against CMV Infection in Patients Undergoing Transplant
https://www.unmc.edu/intmed/divisions/id/asp/protected-antimicrobials/maribavir.html
Maribavir (Livtencity) | Department of Internal Medicine | University of Nebraska Medical Center
Antimicrobial stewardship program at unmc/nebraska medicine information about Maribavir (Livtencity).
department ofinternal medicinemaribavirlivtencityuniversity
https://www.fiercebiotech.com/biotech/takeda-s-maribavir-clears-cytomegalovirus-infections-phase-3
Takeda's maribavir clears cytomegalovirus infections in phase 3 | Fierce Biotech
cytomegalovirus infectionsphase 3takedamaribavirclears
https://www.takeda.com/newsroom/newsreleases/2021/subgroup-analysis-from-phase-3-clinical-trial-supports-efficacy-of-maribavir-over-conventional-therapies-in-transplant-recipients-with-cytomegalovirus-infection/
Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional...
Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection
phase 3 clinical trial